Palvella Therapeutics, Inc. (NASDAQ: PVLA) will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. The clinical-stage biopharmaceutical company will also host a conference call for investors at 8:30 a.m. ET on that date to discuss the financial performance and provide a broader corporate update. This announcement sets the timeline for stakeholders to review the company's progress in developing therapies for serious, rare skin diseases and vascular malformations where no U.S. Food and Drug Administration (FDA)-approved treatments currently exist.

Conference Call Details

Management will lead the discussion during the scheduled call, offering insights into the company's pipeline and operational status. Investors can access the live webcast, which will include presentation slides, via the "Events & Presentations" section of Palvella’s website or through the provided link in the original filing. For those preferring audio access, registration is required via the designated link to receive dial-in details.

A replay of the webcast will be available approximately two hours after the conclusion of the live call. The archived recording will remain accessible for 90 days under the "Events & Presentations" section of the Company’s website at www.palvellatx.com .

Pipeline Overview

Palvella Therapeutics is focused on developing and commercializing novel therapies based on its patented QTORIN™ platform. The company’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas.

The company’s second product candidate, QTORIN™ pitavastatin, is under development for the treatment of disseminated superficial actinic porokeratosis. Both QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and have not been approved by the FDA or any other regulatory agency for any indication.

Key Product Candidates

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. is dedicated to treating patients with lifelong conditions that lack approved therapeutic options. The company continues to advance its broad pipeline of product candidates aimed at addressing unmet medical needs in dermatology and vascular medicine.

Palvella Therapeutics, Inc. has appointed Matt Pauls, J.D., M.B.A., to its Board of Directors, effective June 30, 2026. The appointment aims to strengthen the company's leadership as it advances its pipeline of therapies for serious, rare skin diseases and vascular malformations. Pauls brings over 25 years of experience in developing and commercializing high-impact therapies for diseases with limited or no approved treatment options.

Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics, highlighted Pauls' extensive public company and commercialization expertise. "Over the past decade-plus, Matt’s leadership has contributed to the growth and success of leading public rare disease biotechnology companies, including Savara, Soleno, and Insmed," Kaupinen said. He noted that Pauls' experience will be particularly valuable as Palvella prepares for the potential U.S. launch of QTORIN™ rapamycin.

Pauls has served as Chair of the Board of Directors and Chief Executive Officer of Savara Inc. since 2020. From 2014 to 2019, he was President and Chief Executive Officer of Strongbridge Biopharma plc, where he led the company through its Nasdaq initial public offering and oversaw the commercialization of KEVEYIS® and Macrilen®. Earlier in his career, he served as Chief Commercial Officer of Insmed Incorporated and held senior roles at Shire Pharmaceuticals, Bristol Myers Squibb, and Johnson & Johnson.

From 2023 to 2026, Pauls served on the Board of Soleno Therapeutics, including as Lead Independent Director from 2024 through its $2.9 billion acquisition by Neurocrine Biosciences in 2026. During his tenure, Soleno secured FDA approval and launched VYKAT™ XR, the first FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome. He currently serves on the Boards of Pelthos Therapeutics and Atsena Therapeutics.

Matt Pauls' Professional Background

Pauls expressed confidence in Palvella's strategy, stating, "This is a pivotal time for the company, and I am excited to bring my prior experience to help continue the rapid growth of their business." He holds a B.S. and M.B.A. from Central Michigan University and a J.D. from Michigan State University College of Law.

Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations. Its lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas.